Results 91 to 100 of about 25,511 (203)

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4311-4319, August 2025.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source

Cystic kidney diseases: many ways to form a cyst [PDF]

, 2012
Renal cysts are a common radiological finding in both adults and children. They occur in a variety of conditions, and the clinical presentation, management, and prognosis varies widely.
Loftus, H., Ong, A.C.M.
core   +1 more source

Autosomal dominant polycystic kidney

Pan African Medical Journal, 2022
Gudadhe, Rugaved Raghavendra, Sawarkar, Gaurav Rajendra   +1 more
openaire   +2 more sources

Diffusion Tensor Imaging (DTI) as a Non‐Invasive Tool for Assessing Pediatric Kidney Transplants: A Feasibility Study

Pediatric Transplantation, Volume 29, Issue 5, August 2025.
Our study demonstrates the feasibility of using diffusion tensor imaging (DTI) to evaluate pediatric kidney transplants. Significant differences in fractional anisotropy (FA) and track length were observed between transplanted and healthy kidneys, reflecting altered microstructural organization.
Suraj D. Serai, Tatiana Morales, Daniel Vossough, Sandra Amaral, Hansel J. Otero, Bernarda Viteri Baquerizo   +5 more
wiley   +1 more source

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease [PDF]

, 2010
BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling. METHODS: In this
Kistler, A D, Krauer, F, Kristanto, P, Poster, D, Raina, S, Rentsch, K M, Scheffel, H, Senn, O, Serra, A L, Spanaus, K S, Weishaupt, D, Wüthrich, R P, Young, J   +12 more
core   +1 more source

The power of microRNA regulation—insights into immunity and metabolism

FEBS Letters, Volume 599, Issue 13, Page 1821-1851, July 2025.
MicroRNAs are emerging as crucial regulators at the intersection of metabolism and immunity. This review examines how miRNAs coordinate glucose and lipid metabolism while simultaneously modulating T‐cell development and immune responses. Moreover, it highlights how cutting‐edge artificial intelligence applications can identify miRNA biomarkers ...
Stefania Oliveto, Nicola Manfrini, Stefano Biffo   +2 more
wiley   +1 more source

A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with Autosomal Dominant Polycystic Kidney Disease [PDF]

, 2015
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common form of Polycystic Kidney Disease (PKD) and occurs at a frequency of 1/800 to 1/1000 affecting all ethnic groups worldwide.
Al-Mulla, Fahd, Ali, Hamad, Harris, Peter, Hussain, Naser, Kehinde, Elijah, Naim, Medhat, Seaburg, Lauren, Sundsbak, Jamie, Zayed, Mohamed   +8 more
core  

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

The Pathogenesis of Autosomal Dominant Polycystic Kidney Disease [PDF]

Nephron Experimental Nephrology, 2006
In individuals with autosomal dominant polycystic kidney disease (ADPKD), renal function deteriorates as the kidneys become replaced by multitudes of fluid-filled cysts. Although the PKD genes were identified a decade ago, the pathway(s) leading from mutation to disease remain the subject of intense investigation.
openaire   +3 more sources

Activation of PIEZO1 Attenuates Kidney Cystogenesis In Vitro and Ex Vivo

Kidney360
Key Points. PIEZO1 activation reduces cystogenesis: Yoda1 activates PIEZO1, raising calcium and lowering cAMP, reducing cyst growth in autosomal dominant polycystic kidney disease models.
Qingfeng Fan, Mohamad Hadla, Zack Peterson, Grace Nelson, Hong Ye, Xiaofang Wang, Jean Marc Mardirossian, Peter C. Harris, Seth L. Alper, Y.S. Prakash, Arthur Beyder, Vicente E. Torres, Fouad T. Chebib   +12 more
doaj   +1 more source